Carregant...
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell lung cancer (NSCLC). Upon progressive disease, patients normally receive a subsequent ALK TKI. However, when disease progression occurs in a...
Guardat en:
| Publicat a: | Case Rep Oncol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7383154/ https://ncbi.nlm.nih.gov/pubmed/32774266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000507850 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|